IBRX ImmunityBio Inc

Price (delayed)

$7.305

Market cap

$7.65B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.85

Enterprise value

$8.57B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 19

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer ...

Highlights
ImmunityBio's quick ratio has increased by 35% from the previous quarter
ImmunityBio's revenue has increased by 24% QoQ
ImmunityBio's net income has shrunk by 143% QoQ and by 109% YoY
ImmunityBio's EPS has shrunk by 124% QoQ and by 57% YoY

Key stats

What are the main financial stats of IBRX

IBRX stock price

How has the ImmunityBio stock price performed over time
Intraday
1.74%
1 week
-5.38%
1 month
-1.68%
1 year
149.32%
YTD
268.94%
QTD
-4.76%

Financial performance

How have ImmunityBio's revenue and profit performed over time
Revenue
$140.98M
Gross profit
$140.04M
Operating income
-$261.39M
Net income
-$854.53M
Gross margin
99.3%
Net margin
-606.2%
ImmunityBio's net income has shrunk by 143% QoQ and by 109% YoY
The net margin has dropped by 95% since the previous quarter but it has surged by 54% year-on-year
ImmunityBio's operating margin has soared by 82% YoY and by 18% from the previous quarter
ImmunityBio's revenue has increased by 24% QoQ

Price vs fundamentals

How does IBRX's price correlate with its fundamentals

Growth

What is ImmunityBio's growth rate over time

Valuation

What is ImmunityBio stock price valuation
P/E
N/A
P/B
N/A
P/S
53.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60.78
ImmunityBio's EPS has shrunk by 124% QoQ and by 57% YoY
ImmunityBio's equity has shrunk by 74% QoQ and by 47% YoY
The P/S is 98% less than the 5-year quarterly average of 3312.1 but 48% more than the last 4 quarters average of 35.4
ImmunityBio's revenue has increased by 24% QoQ

Efficiency

How efficient is ImmunityBio business performance
The company's return on invested capital has shrunk by 180% QoQ and by 150% YoY
ImmunityBio's return on sales has shrunk by 150% QoQ but it has increased by 38% YoY
IBRX's return on assets has dropped by 103% since the previous quarter and by 51% year-on-year

Dividends

What is IBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IBRX.

Financial health

How did ImmunityBio financials performed over time
The total assets is 57% less than the total liabilities
The total assets has soared by 113% YoY and by 29% from the previous quarter
ImmunityBio's total liabilities has soared by 70% YoY and by 51% from the previous quarter
ImmunityBio's equity has shrunk by 74% QoQ and by 47% YoY
The debt rose by 37% year-on-year and by 33% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.